This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción 4OD
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Competidores de Odonate, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.28 |
| 52 Week High | US$1.46 |
| 52 Week Low | US$1.08 |
| Beta | 0.062 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -95.71% |
| 5 Year Change | n/a |
| Change since IPO | -93.58% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 4OD | DE Pharmaceuticals | Mercado DE | |
|---|---|---|---|
| 7D | 0% | -3.1% | -2.0% |
| 1Y | n/a | -31.9% | -0.3% |
Rentabilidad vs. Industria: Insufficient data to determine how 4OD performed against the German Pharmaceuticals industry.
Rentabilidad vs. Mercado: Insufficient data to determine how 4OD performed against the German Market.
Volatilidad de los precios
| 4OD volatility | |
|---|---|
| 4OD Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: 4OD has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: Insufficient data to determine 4OD's volatility change over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2013 | 145 | Kevin Tang | www.odonate.com |
Resumen de fundamentos de Odonate, Inc.
| Estadísticas fundamentales de 4OD | |
|---|---|
| Capitalización bursátil | €43.79m |
| Beneficios(TTM) | -€101.27m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-0.4x
Ratio precio-beneficio (PE)¿Está 4OD sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 4OD | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$102.07m |
| Beneficios | -US$102.07m |
Últimos beneficios comunicados
Sep 30, 2021
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -3.47 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado 4OD a largo plazo?
Ver rendimiento histórico y comparativa